{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:59:41Z","timestamp":1780678781118,"version":"3.54.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001655","name":"Grayson-Jockey Club Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Equine herpesvirus type 1 (EHV-1) is a highly transmissible pathogen that leads to a variety of clinical disease outcomes in infected horses. A major sequela that can occur after an EHV-1 infection is a neurological disease termed equine herpesvirus myeloencephalopathy (EHM). Clinical manifestations of EHM include fever, ataxia, incontinence, and partial to full paralysis, which may ultimately lead to the euthanization of the infected horse. To develop an effective treatment strategy for EHM, it is critical that the specific virus\u2013host interactions that lead to EHM be investigated so that safe and effective therapeutic interventions can be developed and delivered. In this study, we examined the ability of four non-steroidal anti-inflammatory drugs (NSAIDs), a steroidal anti-inflammatory drug (dexamethasone), a Rho-kinase (ROCK) inhibitor, and a JAK\/STAT inhibitor (AG490) to reduce EHV-1 virus yields and cell-to-cell spread. We show that the NSAID, flunixin meglumine (FM), and the JAK\/STAT inhibitor, AG490, significantly reduced virus yields in endothelial and epithelial cell lines, and this inhibition was similar for two neurologic and two non-neurologic EHV-1 strains. In addition to reducing virus yields, AG490 and FM also significantly reduced the ability of EHV-1 to spread laterally from cell to cell.<\/jats:p>","DOI":"10.3389\/fvets.2023.1165917","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:06:25Z","timestamp":1684472785000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-inflammatory compounds reduce equine herpesvirus type 1 replication and cell-to-cell spread"],"prefix":"10.3389","volume":"10","author":[{"given":"Jeanette B.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur R.","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"B1","first-page":"78","article-title":"Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections","volume":"2","author":"Allen","year":"1986","journal-title":"Prog Vet Microbiol Immunol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-4684-7012-3_5","article-title":"The equine herpesviruses","volume-title":"The Herpesviruses, Comprehensive Virology","author":"O'Callaghan","year":"1983"},{"key":"B3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0749-0739(17)30396-6","article-title":"The equine herpesviruses","volume":"9","author":"Ostlund","year":"1993","journal-title":"Vet Clin N Am Equine Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1371\/journal.ppat.0030160","article-title":"A point mutation in a herpesvirus polymerase determines neuropathogenicity","volume":"3","author":"Goodman","year":"2007","journal-title":"PLoS Pathog."},{"key":"B5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.vetmic.2009.06.033","article-title":"Investigation of the prevalence of neurologic equine herpes virus type 1 (EHV-1) in a 23-year retrospective analysis (1984-2007)","volume":"139","author":"Perkins","year":"2009","journal-title":"Vet Microbiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1128\/JVI.80.8.4047-4060.2006","article-title":"Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks","volume":"80","author":"Nugent","year":"2006","journal-title":"J Virol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.vetmic.2009.07.030","article-title":"The increased prevalence of neuropathogenic strains of EHV-1 in equine abortions","volume":"141","author":"Smith","year":"2010","journal-title":"Vet Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/104063870701900110","article-title":"Development of a real-time polymerase chain reaction assay for rapid diagnosis of neuropathogenic strains of equine herpesvirus-1","volume":"19","author":"Allen","year":"2007","journal-title":"J Vet Diagn Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1086\/599316","article-title":"single-nucleotide polymorphism in a herpesvirus DNA polymerase is sufficient to cause lethal neurological disease","volume":"200","author":"Van de Walle","year":"2009","journal-title":"J Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2460\/ajvr.69.12.1595","article-title":"Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses","volume":"69","author":"Allen","year":"2008","journal-title":"Am J Vet Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2746\/042516406776866453","article-title":"Quantification by real-time PCR of the magnitude and duration of leucocyte-associated viraemia in horses infected with neuropathogenic vs. non-neuropathogenic strains of EHV-1","volume":"38","author":"Allen","year":"2006","journal-title":"Equine Vet J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cveq.2014.08.006","article-title":"Equine herpesvirus 1 myeloencephalopathy","volume":"30","author":"Pusterla","year":"2014","journal-title":"Vet Clin N Am Equine Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF01314149","article-title":"Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: equine stroke","volume":"90","author":"Edington","year":"1986","journal-title":"Arch Virol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.vetimm.2011.06.032","article-title":"Infection of peripheral blood mononuclear cells with neuropathogenic equine herpesvirus type-1 strain Ab4 reveals intact interferon-alpha induction and induces suppression of anti-inflammatory interleukin-10 responses in comparison to other viral strains","volume":"143","author":"Wagner","year":"2011","journal-title":"Vet Immunol Immunopathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.2042-3306.2012.00604.x","article-title":"Third International Havemeyer Workshop on Equine Herpesvirus type 1","volume":"44","author":"Kydd","year":"2012","journal-title":"Equine Vet J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.vetmic.2016.06.012","article-title":"Equine herpesvirus type 1 modulates inflammatory host immune response genes in equine endothelial cells","volume":"192","author":"Johnstone","year":"2016","journal-title":"Vet Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"12964","DOI":"10.1128\/JVI.78.23.12964-12974.2004","article-title":"Cyclooxygenase-1 and\u22122 are required for production of infectious pseudorabies virus","volume":"78","author":"Ray","year":"2004","journal-title":"J Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/v10090457","article-title":"Antiviral effect of resveratrol in piglets infected with virulent pseudorabies virus","author":"Zhao","year":"2018","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1128\/JVI.00352-19","article-title":"Replication of Marek's disease virus is dependent on synthesis of de novo fatty acid and prostaglandin E2","author":"Boodhoo","year":"2019","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19468","DOI":"10.1073\/pnas.0810740105","article-title":"Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus","volume":"105","author":"Schroer","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1073\/pnas.052713799","article-title":"Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication","volume":"99","author":"Zhu","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.nbd.2016.02.007","article-title":"The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model","volume":"92","author":"Haile","year":"2016","journal-title":"Neurobiol Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1033672","DOI":"10.3389\/fimmu.2022.1033672","article-title":"Repurposing BCL-2 and Jak 1\/2 inhibitors: cure and treatment of HIV-1 and other viral infections","volume":"13","author":"Reece","year":"2022","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12974-019-1565-6","article-title":"Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro","volume":"16","author":"Gavegnano","year":"2019","journal-title":"J Neuroinflammation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.20411\/pai.v2i2.190","article-title":"Jak inhibitors modulate production of replication-competent zika virus in human hofbauer, trophoblasts, and neuroblastoma cells","volume":"2","author":"Gavegnano","year":"2017","journal-title":"Pathog Immun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","author":"Stebbing","year":"2021","journal-title":"Sci Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fcimb.2018.00312","article-title":"Abortigenic but not neurotropic equine herpes virus 1 modulates the interferon antiviral defense","volume":"8","author":"Poelaert","year":"2018","journal-title":"Front Cell Infect Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.virol.2004.07.034","article-title":"Equine herpesvirus type 1 (EHV-1) glycoprotein K is required for efficient cell-to-cell spread and virus egress","volume":"329","author":"Neubauer","year":"2004","journal-title":"Virology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0168-1702(02)00245-9","article-title":"Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model","volume":"90","author":"Frampton AR","year":"2002","journal-title":"Virus Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2460\/javma.250.11.1271","article-title":"Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses","volume":"250","author":"Ziegler","year":"2017","journal-title":"J Am Vet Med Assoc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cveq.2016.11.001","article-title":"Nonsteroidal anti-inflammatory drug use in horses","volume":"33","author":"Knych","year":"2017","journal-title":"Vet Clin N Am Equine Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jevs.2015.02.012","article-title":"Anti-inflammatory drugs in equine neonatal medicine. Part II: corticosteroids","volume":"35","author":"Castagnetti","year":"2015","journal-title":"J Eq Vet Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/jvim.13834","article-title":"Equine protozoal myeloencephalitis: an updated consensus statement with a focus on parasite biology, diagnosis, treatment, and prevention","volume":"30","author":"Reed","year":"2016","journal-title":"J Vet Int Med."},{"key":"B34","article-title":"Anti-inflammatory drugs decrease the rate of endothelial cell infection with EHV-1 in vitro","volume-title":"Proceedings of 2012 Veterinary Symposium","author":"Goehring","year":"2012"},{"key":"B35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1128\/JVI.01342-19","article-title":"Equid herpesvirus 1 targets the sensitization and induction steps to inhibit the type I interferon response in equine endothelial cells","author":"Oladunni","year":"2019","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vetimm.2016.03.009","article-title":"Equine herpesvirus-1 infection disrupts interferon regulatory factor-3 (IRF-3) signaling pathways in equine endothelial cells","volume":"173","author":"Sarkar","year":"2016","journal-title":"Vet Immunol Immunopathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1023\/B:VIRU.0000032785.19420.14","article-title":"Meningoencephalitis in mice infected with an equine herpesvirus 1 strain KyA recombinant expressing glycoprotein I and glycoprotein E","volume":"29","author":"Frampton AR","year":"2004","journal-title":"Virus Genes."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2460\/ajvr.78.10.1126","article-title":"Efficacy of the early administration of valacyclovir hydrochloride for the treatment of neuropathogenic equine herpesvirus type-1 infection in horses","volume":"78","author":"Maxwell","year":"2017","journal-title":"Am J Vet Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.vetmic.2009.07.035","article-title":"Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells","volume":"141","author":"Frampton AR","year":"2010","journal-title":"Vet Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"10879","DOI":"10.1128\/JVI.00504-07","article-title":"Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1","volume":"81","author":"Frampton AR","year":"2007","journal-title":"J Virol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001317","article-title":"Equine herpesvirus 1 infection orchestrates the expression of chemokines in equine respiratory epithelial cells","author":"Poelaert","year":"2019","journal-title":"J Gen Virol."},{"key":"B42","first-page":"11","article-title":"Oral administration of valganciclovir reduces clinical signs, virus shedding and cell-associated viremia in ponies experimentally infected with the equid herpesvirus-1 C(2254) variant","author":"Thieulent","year":"2022","journal-title":"Pathogens"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2023.1165917\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:06:32Z","timestamp":1684472792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2023.1165917\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":42,"alternative-id":["10.3389\/fvets.2023.1165917"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2023.1165917","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"article-number":"1165917"}}